Inventiva (IVA) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free IVA Stock Alerts $3.56 +0.18 (+5.33%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 2:30 AM | globenewswire.comInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorApril 28, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Short Interest UpdateInventiva S.A. (NASDAQ:IVA - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average trading volume of 39,500 shares, the short-interest ratio is currently 2.0 days.April 26, 2024 | wsj.comInventiva S.A. ADRApril 19, 2024 | msn.comHepion ends Phase 2 study for NASH drug due to cash restraintsApril 8, 2024 | marketbeat.comCanaccord Genuity Group Increases Inventiva (NASDAQ:IVA) Price Target to $20.00Canaccord Genuity Group lifted their price objective on shares of Inventiva from $12.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday.April 4, 2024 | marketbeat.comInventiva S.A. Expected to Earn FY2025 Earnings of ($2.92) Per Share (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Inventiva in a research note issued on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will earn ($2.92) per share for the year, up from their preApril 3, 2024 | globenewswire.comInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FApril 3, 2024 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for Inventiva S.A. (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright boosted their FY2028 EPS estimates for Inventiva in a report released on Monday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will earn $2.45 per share for the year, up from theirApril 1, 2024 | msn.comJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical TrialsApril 1, 2024 | finance.yahoo.comInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call TranscriptApril 1, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Inventiva in a research report on Monday.March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)March 28, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | globenewswire.comInventiva announces the nomination of Andre Turenne as DirectorMarch 27, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 full-year resultsMarch 27, 2024 | globenewswire.comInventiva reports its 2023 full-year resultsMarch 22, 2024 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsMarch 21, 2024 | markets.businessinsider.comPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH TreatmentMarch 20, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of Inventiva in a research note on Wednesday.March 20, 2024 | marketbeat.comInventiva (IVA) to Release Quarterly Earnings on WednesdayInventiva (NASDAQ:IVA) will be releasing earnings after the market closes on Wednesday, March 27, Zacks reports.March 18, 2024 | markets.businessinsider.comPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA ApprovalMarch 18, 2024 | globenewswire.comInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DMarch 18, 2024 | seekingalpha.comMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH LeadMarch 14, 2024 | bizjournals.comShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentMarch 13, 2024 | globenewswire.comInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DMarch 8, 2024 | markets.businessinsider.comInventiva’s Clinical Progress and Financial Valuation Reinforce Buy RatingMarch 8, 2024 | markets.businessinsider.comInventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising OutlookMarch 7, 2024 | globenewswire.comInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedFebruary 23, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) to Post FY2023 Earnings of ($2.26) Per Share, HC Wainwright ForecastsInventiva S.A. (NASDAQ:IVA - Free Report) - Investment analysts at HC Wainwright upped their FY2023 earnings per share estimates for shares of Inventiva in a research note issued to investors on Tuesday, February 20th. HC Wainwright analyst E. Arce now anticipates that the company will earn ($2.2February 17, 2024 | markets.businessinsider.comBuy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety RecordFebruary 16, 2024 | msn.comInventiva halt recruitment for Phase III NASH trial following adverse eventFebruary 16, 2024 | marketbeat.comStifel Nicolaus Cuts Inventiva (NASDAQ:IVA) Price Target to $25.00Stifel Nicolaus reduced their price target on Inventiva from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Friday.February 16, 2024 | marketwatch.comInventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse EventFebruary 15, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3February 15, 2024 | finance.yahoo.comInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3February 15, 2024 | globenewswire.comInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3February 6, 2024 | msn.com11 of the Best Investing Books for BeginnersFebruary 4, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of "Buy" from BrokeragesInventiva S.A. (NASDAQ:IVA - Get Free Report) has received an average rating of "Buy" from the eight brokerages that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have updatedJanuary 31, 2024 | msn.comFDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4January 31, 2024 | morningstar.comInventiva SA ADR IVAJanuary 24, 2024 | markets.businessinsider.comHalf-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxJanuary 24, 2024 | finanznachrichten.deINVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJanuary 17, 2024 | finance.yahoo.comNon-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsightJanuary 10, 2024 | finanznachrichten.deINVENTIVA: Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment BankJanuary 9, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Earns "Outperform" Rating from Lifesci CapitalLifesci Capital reissued an "outperform" rating on shares of Inventiva in a research note on Friday.December 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Annexon Biosciences (ANNX)December 21, 2023 | marketbeat.comInventiva (NASDAQ:IVA) Price Target Lowered to $24.00 at HC WainwrightHC Wainwright dropped their price target on Inventiva from $36.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday.December 20, 2023 | finance.yahoo.comInventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development programDecember 17, 2023 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Sees Large Decline in Short InterestInventiva S.A. (NASDAQ:IVA - Get Free Report) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 83,800 shares, a decrease of 6.6% from the November 15th total of 89,700 shares. Based on an average daily trading volume, of 10,800 shares, the short-interest ratio is presently 7.8 days. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. IVA Media Mentions By Week IVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.960.58▲Average Medical News Sentiment IVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼32▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SCPH News Today TELO News Today OGI News Today GLSI News Today ALIM News Today CAPR News Today MCRB News Today GOSS News Today ACRV News Today PRQR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
